Selected research
Industry Research
Diabetes Screening Industry Research Report 2026
Market perspective
The global Diabetes Screening market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Diabetes Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Diabetes Screening market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Diabetes Screening market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Diabetes Screening include InSphero AG, Abbott Laboratories, American Laboratory Products Company (ALPCO), Beckmann Coulter Inc., Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics Inc., F. Hoffmann-la Roche Ltd, Siemens AG and PTS Diagnostics. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Diabetes Screening market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Diabetes Screening.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Diabetes Screening Market by Company
InSphero AG
Abbott Laboratories
American Laboratory Products Company (ALPCO)
Beckmann Coulter Inc.
Bio-Rad Laboratories Inc.
Ortho Clinical Diagnostics Inc.
F. Hoffmann-la Roche Ltd
Siemens AG
PTS Diagnostics
Diabetes Screening Segment by Type
Instrument
Test Suite
Reagents
Diabetes Screening Segment by Application
Hospital
Specialty Clinic
Diagnostic Center
Home Care
Academic Research Institution
Diabetes Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetes Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Diabetes Screening companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Instrument
- Test Suite
- Reagents
Applications
- Hospital
- Specialty Clinic
- Diagnostic Center
- Home Care
- Academic Research Institution
Companies covered
- InSphero AG
- Abbott Laboratories
- American Laboratory Products Company (ALPCO)
- Beckmann Coulter Inc.
- Bio-Rad Laboratories Inc.
- Ortho Clinical Diagnostics Inc.
- F. Hoffmann-la Roche Ltd
- Siemens AG
- PTS Diagnostics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Diabetes Screening by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Instrument
- 2.2.3 Test Suite
- 2.2.4 Reagents
- 2.3 Diabetes Screening by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Specialty Clinic
- 2.3.4 Diagnostic Center
- 2.3.5 Home Care
- 2.3.6 Academic Research Institution
- 2.4 Assumptions and Limitations
3 Diabetes Screening Breakdown Data by Type
- 3.1 Global Diabetes Screening Historic Market Size by Type (2021-2026)
- 3.2 Global Diabetes Screening Forecasted Market Size by Type (2027-2032)
4 Diabetes Screening Breakdown Data by Application
- 4.1 Global Diabetes Screening Historic Market Size by Application (2021-2026)
- 4.2 Global Diabetes Screening Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Diabetes Screening Market Perspective (2021-2032)
- 5.2 Global Diabetes Screening Growth Trends by Region
- 5.2.1 Global Diabetes Screening Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Diabetes Screening Historic Market Size by Region (2021-2026)
- 5.2.3 Diabetes Screening Forecasted Market Size by Region (2027-2032)
- 5.3 Diabetes Screening Market Dynamics
- 5.3.1 Diabetes Screening Industry Trends
- 5.3.2 Diabetes Screening Market Drivers
- 5.3.3 Diabetes Screening Market Challenges
- 5.3.4 Diabetes Screening Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Diabetes Screening Players by Revenue
- 6.1.1 Global Top Diabetes Screening Players by Revenue (2021-2026)
- 6.1.2 Global Diabetes Screening Revenue Market Share by Players (2021-2026)
- 6.2 Global Diabetes Screening Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Diabetes Screening Head Office and Area Served
- 6.4 Global Diabetes Screening Players, Product Type & Application
- 6.5 Global Diabetes Screening Manufacturers Established Date
- 6.6 Global Diabetes Screening Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Diabetes Screening Market Size (2021-2032)
- 7.2 North America Diabetes Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Diabetes Screening Market Size by Country (2021-2026)
- 7.4 North America Diabetes Screening Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Diabetes Screening Market Size (2021-2032)
- 8.2 Europe Diabetes Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Diabetes Screening Market Size by Country (2021-2026)
- 8.4 Europe Diabetes Screening Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Diabetes Screening Market Size (2021-2032)
- 9.2 Asia-Pacific Diabetes Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Diabetes Screening Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Diabetes Screening Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Diabetes Screening Market Size (2021-2032)
- 10.2 South America Diabetes Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Diabetes Screening Market Size by Country (2021-2026)
- 10.4 South America Diabetes Screening Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Diabetes Screening Market Size (2021-2032)
- 11.2 Middle East & Africa Diabetes Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Diabetes Screening Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Diabetes Screening Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 InSphero AG
- 12.1.1 InSphero AG Company Information
- 12.1.2 InSphero AG Business Overview
- 12.1.3 InSphero AG Revenue in Diabetes Screening Business (2021-2026)
- 12.1.4 InSphero AG Diabetes Screening Product Portfolio
- 12.1.5 InSphero AG Recent Developments
- 12.2 Abbott Laboratories
- 12.2.1 Abbott Laboratories Company Information
- 12.2.2 Abbott Laboratories Business Overview
- 12.2.3 Abbott Laboratories Revenue in Diabetes Screening Business (2021-2026)
- 12.2.4 Abbott Laboratories Diabetes Screening Product Portfolio
- 12.2.5 Abbott Laboratories Recent Developments
- 12.3 American Laboratory Products Company (ALPCO)
- 12.3.1 American Laboratory Products Company (ALPCO) Company Information
- 12.3.2 American Laboratory Products Company (ALPCO) Business Overview
- 12.3.3 American Laboratory Products Company (ALPCO) Revenue in Diabetes Screening Business (2021-2026)
- 12.3.4 American Laboratory Products Company (ALPCO) Diabetes Screening Product Portfolio
- 12.3.5 American Laboratory Products Company (ALPCO) Recent Developments
- 12.4 Beckmann Coulter Inc.
- 12.4.1 Beckmann Coulter Inc. Company Information
- 12.4.2 Beckmann Coulter Inc. Business Overview
- 12.4.3 Beckmann Coulter Inc. Revenue in Diabetes Screening Business (2021-2026)
- 12.4.4 Beckmann Coulter Inc. Diabetes Screening Product Portfolio
- 12.4.5 Beckmann Coulter Inc. Recent Developments
- 12.5 Bio-Rad Laboratories Inc.
- 12.5.1 Bio-Rad Laboratories Inc. Company Information
- 12.5.2 Bio-Rad Laboratories Inc. Business Overview
- 12.5.3 Bio-Rad Laboratories Inc. Revenue in Diabetes Screening Business (2021-2026)
- 12.5.4 Bio-Rad Laboratories Inc. Diabetes Screening Product Portfolio
- 12.5.5 Bio-Rad Laboratories Inc. Recent Developments
- 12.6 Ortho Clinical Diagnostics Inc.
- 12.6.1 Ortho Clinical Diagnostics Inc. Company Information
- 12.6.2 Ortho Clinical Diagnostics Inc. Business Overview
- 12.6.3 Ortho Clinical Diagnostics Inc. Revenue in Diabetes Screening Business (2021-2026)
- 12.6.4 Ortho Clinical Diagnostics Inc. Diabetes Screening Product Portfolio
- 12.6.5 Ortho Clinical Diagnostics Inc. Recent Developments
- 12.7 F. Hoffmann-la Roche Ltd
- 12.7.1 F. Hoffmann-la Roche Ltd Company Information
- 12.7.2 F. Hoffmann-la Roche Ltd Business Overview
- 12.7.3 F. Hoffmann-la Roche Ltd Revenue in Diabetes Screening Business (2021-2026)
- 12.7.4 F. Hoffmann-la Roche Ltd Diabetes Screening Product Portfolio
- 12.7.5 F. Hoffmann-la Roche Ltd Recent Developments
- 12.8 Siemens AG
- 12.8.1 Siemens AG Company Information
- 12.8.2 Siemens AG Business Overview
- 12.8.3 Siemens AG Revenue in Diabetes Screening Business (2021-2026)
- 12.8.4 Siemens AG Diabetes Screening Product Portfolio
- 12.8.5 Siemens AG Recent Developments
- 12.9 PTS Diagnostics
- 12.9.1 PTS Diagnostics Company Information
- 12.9.2 PTS Diagnostics Business Overview
- 12.9.3 PTS Diagnostics Revenue in Diabetes Screening Business (2021-2026)
- 12.9.4 PTS Diagnostics Diabetes Screening Product Portfolio
- 12.9.5 PTS Diagnostics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst